Stoke Therapeutics, Inc. (FRA:0GT)

Market Cap	1.66B +157.5%
Revenue (ttm)	175.26M +1,128.2%
Net Income	34.58M
EPS	0.58
Shares Out	n/a
PE Ratio	48.08
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	29.00
Previous Close	26.00
Day's Range	29.00 - 29.00
52-Week Range	5.20 - 32.60
Beta	n/a
RSI	63.28
Earnings Date	Mar 6, 2026

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine f...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 128
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0GT

Financial Performance

In 2024, Stoke Therapeutics's revenue was $36.56 million, an increase of 316.34% compared to the previous year's $8.78 million. Losses were -$88.98 million, -15.01% less than in 2023.

Financial numbers in USD